Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Long-Term Debt Issuances (2018 - 2023)

Endonovo Therapeutics has reported Long-Term Debt Issuances over the past 12 years, most recently at $49000.0 for Q3 2023.

  • Quarterly results put Long-Term Debt Issuances at $49000.0 for Q3 2023, down 67.33% from a year ago — trailing twelve months through Sep 2023 was $414000.0 (down 52.69% YoY), and the annual figure for FY2022 was $465000.0, down 51.05%.
  • Long-Term Debt Issuances for Q3 2023 was $49000.0 at Endonovo Therapeutics, down from $65000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for ENDV hit a ceiling of $1.2 million in Q2 2019 and a floor of $49000.0 in Q3 2023.
  • Median Long-Term Debt Issuances over the past 5 years was $164924.0 (2020), compared with a mean of $271141.1.
  • Biggest five-year swings in Long-Term Debt Issuances: surged 433.33% in 2019 and later tumbled 86.32% in 2022.
  • Endonovo Therapeutics' Long-Term Debt Issuances stood at $500000.0 in 2019, then tumbled by 58.66% to $206693.0 in 2020, then surged by 129.81% to $475000.0 in 2021, then tumbled by 86.32% to $65000.0 in 2022, then dropped by 24.62% to $49000.0 in 2023.
  • The last three reported values for Long-Term Debt Issuances were $49000.0 (Q3 2023), $65000.0 (Q4 2022), and $150000.0 (Q3 2022) per Business Quant data.